KIYATEC is a company specializing in oncology treatment. It uses ex vivo 3D cell culture technology platform to model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company also focuses on the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors.